Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47–53.

PubMed  PubMed Central  Google Scholar 

Chong X, Madeti Y, Cai J, et al. Recent developments in immunotherapy for gastrointestinal tract cancers[J]. J Hematology & Oncol. 2024;17(1):65.

Article  Google Scholar 

Dunn GP, Old LJ, Schreiber RD. The Three Es of Cancer Immunoediting[J]. Annu Rev Immunol. 2004;22(1):329–60.

Article  CAS  PubMed  Google Scholar 

Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197–208.

Article  CAS  PubMed  Google Scholar 

Janjigian YY, Shitara K, Moehler M, et al. First-line Nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet. 2021;398(10294):27–40.

Article  CAS  Google Scholar 

Shitara K, Van Cutsem E, Bang Y, et al. Efficacy and safety of Pembrolizumab or Pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer. JAMA Oncol. 2020;6(10):1571.

Article  PubMed  PubMed Central  Google Scholar 

Lee C, Kim HS, Jung M, et al. Open-label, multicenter, randomized, biomarker-integrated umbrella trial for second-line treatment of advanced gastric cancer: K-Umbrella Gastric Cancer Study. J Clin Oncol. 2024;42(3):348–57.

Article  CAS  PubMed  Google Scholar 

Pang K, Shi Z, Wei L, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade. Drug Resist Updates. 2023;66:100907.

Article  CAS  Google Scholar 

Kluger HM, Tawbi HA, Ascierto ML, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J Immunother Cancer. 2020. https://doi.org/10.1136/jitc-2019-000398.

Article  PubMed  PubMed Central  Google Scholar 

Wang F, Zhang X, Tang L, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.[J]. Cancer communications (London, England), 2024,44(1):127–172.

Sun J, Zhang D, Wu S, et al. Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark Res. 2020;8:35.

Article  PubMed  PubMed Central  Google Scholar 

Liu K, Yuan S, Wang C, et al. Resistance to immune checkpoint inhibitors in gastric cancer. Front Pharmacol. 2023;14:1285343.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yasuda T, Wang YA. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer. 2024;10(7):627–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin M, Fang J, Peng J, et al. PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies. Mol Cancer. 2024;23(1):266.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee SH, Lee D, Choi J, et al. Spatial dissection of tumour microenvironments in gastric cancers reveals the immunosuppressive crosstalk between CCL2+ fibroblasts and STAT3-activated macrophages. Gut. 2024. https://doi.org/10.1136/gutjnl-2024-332901.

Article  PubMed  PubMed Central  Google Scholar 

Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang H, Liu L, Liu J, et al. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22(1):58.

Article  PubMed  PubMed Central  Google Scholar 

Zhang G, Zhang X, Pan W, et al. Dissecting the spatial and single-cell transcriptomic architecture of cancer stem cell niche driving tumor progression in gastric cancer. Adv Sci. 2025;12(18):e2413019.

Article  Google Scholar 

An M, Mehta A, Min BH, et al. Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer. Cancer Discov. 2024;14(5):766–85.

Article  CAS  PubMed  Google Scholar 

Yang Y, Li J, Lei W, et al. CXCL12-CXCR4/CXCR7 axis in cancer: from mechanisms to clinical applications. Int J Biol Sci. 2023;19(11):3341–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daniel SK, Seo YD, Pillarisetty VG. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies. Semin Cancer Biol. 2020;65:176–88.

Article  CAS  PubMed  Google Scholar 

Huynh C, Dingemanse J, Meyer Zu Schwabedissen HE, et al. Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions. Pharmacol Res. 2020;161:105092.

Article  CAS  PubMed  Google Scholar 

Anastasiadou DP, Quesnel A, Duran CL, et al. An emerging paradigm of CXCL12 involvement in the metastatic cascade. Cytokine Growth Factor Rev. 2024;75:12–30.

Article  CAS  PubMed  Google Scholar 

Li J, Shu X, Xu J, et al. S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy. Nat Commun. 2022;13(1):1481.

Article  PubMed  PubMed Central  Google Scholar 

Chen D, Sheng H, Zhang D, et al. The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141–3p[J]. Mol Cancer. 2021;20(1):166.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fan HC, Fu GK, Fodor SPA. Expression profiling. Combinatorial labeling of single cells for gene expression cytometry. Science (New York, NY). 2015;347(6222):1258367.

Article  Google Scholar 

Butler A, Hoffman P, Smibert P, et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36(5):411–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stuart T, Butler A, Hoffman P, et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888–902.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aran D, Looney AP, Liu L, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019;20(2):163–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lomenick B, Hao R, Jonai N, et al. Target identification using drug affinity responsive target stability (DARTS). Proceed National Acad Sci United States Am. 2009;106(51):21984–9.

Article  CAS  Google Scholar 

Chen J, Jiang CC, Jin L, et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27(3):409–16.

Article  CAS  PubMed  Google Scholar 

Balamurugan K. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer. 2016;138(5):1058–66.

Article  CAS  PubMed